We’re headed back to Baltimore! The ECOG-ACRIN Spring 2026 Group Meeting will be held May 5–7, 2026 (Tues–Thurs, note the shift from Wed–Fri). Join us in Baltimore for plenary sessions, networking, and collaboration. Stay tuned for registration details. #EAOnc
The Fall 2025 Group Meeting session recordings are now available on the Attendee Hub Website.
Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc
Day 2 of the #EAOnc Fall 2025 Group Meeting is underway! Let us know which sessions you are heading to today. And don’t miss our General Session at 5:30 PM! 🩺🩻📈
Group Co-Chair Dr. Mitch Schnall of @pennmedicine.bsky.social kicks off the Fall 2025 Robert L. Comis Translational Science Symposium, focused on #AI, #RealWorldData, and alternative approaches to phase 2 and 3 therapeutic questions. #EAOnc
The Robert L. Comis, MD Translational Science Symposium on Approaches Using #AI and Other Electronic Methods in #ClinicalTrials is underway. Join us in Salon E, 5th Floor! #EAOnc #CancerResearch
Congratulations to the Fall 2025 Edith Peterson Mitchell, MD Travel Scholars! #CancerResearch #ClinicalTrials #EAOnc
The #EAOnc Fall 2025 Group Meeting officially begins today! Looking forward to seeing you in Philadelphia. Check in at the registration desk on the 5th floor before heading to your first session. 🩺🩻📈
Today is #WorldCancerResearchDay! Catch up on the latest
@eaonc.bsky.social research highlights from our August newsletter here ➡️https://bit.ly/aug25research #EAOnc #CancerResearch
ICYMI: Check out our round-up of recently published
@eaonc.bsky.social research results. More here ➡️ bit.ly/aug25research #EAOnc
Submit an Abstract for the 2025 Young Investigator Symposium by Thursday, 9/11! 🩻
We are now accepting research abstracts from early-career investigators interested in presenting your research as part of the upcoming Fall 2025 Group Meeting. More: bit.ly/yis-fall25 #EAOnc
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
👏 Congrats to OUCH-I Chair & Founder Dr. Joan H. Schiller on winning the 2025 #EAOnc Remarkable Mentor in Oncology Award, a true leader in lung cancer research & mentorship! #LungCancer #Oncology #Mentorship #OUCH
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD ow.ly/aVr250BZ0dw #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
Powerful talk on building strong patient-oncologist relationships by #CancerResearch advocate and #KidneyCancer survivor Glenn Sykes during our Spring 2025 General Session. #EAOnc
Congratulations to the 2025 #EAOnc Remarkable Mentor in Oncology Award recipient, Dr. Joan Schiller of @lungcancerresearch.bsky.social @ouchinternational.bsky.social! #mentorship #LungCancer
Congratulations to Dr. Zachary Avigan of the Icahn School of Medicine at Mount Sinai on receiving the 2025 #EAOnc Paul Carbone, MD Fellowship Award! #CancerResearch #ClinicalTrials #MultipleMyeloma
Congratulations to @pgrivasmdphd.bsky.social of @uwmedicine.bsky.social @fredhutch.bsky.social on receiving the 2025 #EAOnc Young Investigator Award. Well deserved! #CancerResearch #ClinicalTrials #BladderCancer
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD ow.ly/aVr250BZ0dw #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
The #EAOnc Spring 2025 Group Meeting officially begins today. Looking forward to seeing you in Tampa. Let us know which sessions you plan on attending! 📈🩺
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD ow.ly/aVr250BZ0dw #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
